← All Olema Pharmaceuticals, INC filings

Olema Pharmaceuticals, INC 8-K filings

NASDAQ
OLMA
Olema Pharmaceuticals, INC
8-K: Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Olema Pharmaceuticals reported its Q1 2024 financial results, highlighted clinical trial progress, and provided updates on its drug development programs.
NASDAQ
OLMA
Olema Pharmaceuticals, INC
8-K: Olema Oncology Reports Full-Year 2023 Financial Results and Provides Corporate Update
Olema Pharmaceuticals reported its 2023 financial results, highlighted clinical progress with palazestrant, and announced a new development candidate for their KAT6 program.